SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”
7 references·2 citing·44 second hop
USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT” (2012)USING HEALTH TECHNOLOGY ASSESSMENT TO SUP…What principles should govern the use of managed entry agreements? (2011)What principles should govern…Access with Evidence Development Schemes (2010)Access with Evidence Developm…Identifying existing health care services that do not provide value for money (2009)Identifying existing health c…Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices (2008)Exploring policy-makers’ pers…BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS (2002)BEST PRACTICE IN UNDERTAKING …Prospect Theory: An Analysis of Decision under Risk (2000)Prospect Theory: An Analysis …Prospect theory: An analysis of decision under risk (1988)Prospect theory: An analysis …HTA Implementation Roadmap in Central and Eastern European Countries (2016)HTA Implementation Roadmap in…How OECD health systems define the range of good and services to be financed collectively (2016)How OECD health systems defin…Key issues in health economics (1994)HTA 101 INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT (2004)Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications (2011)CASE STUDIES THAT ILLUSTRATE DISINVESTMENT AND RESOURCE ALLOCATION DECISION-MAKING PROCESSES IN HEALTH CARE: A SYSTEMATIC REVIEW (2013)Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review (2015)Comparative Effectiveness Research: A Report From the Institute of Medicine (2009)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries (2013)Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (2014)The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement (1999)Qualitative research in health care: Assessing quality in qualitative research (2000)Patient-based health technology assessment: A vision of the future (2007)Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA) (2011)Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis (2003)Exploring Uncertainty in Cost-Effectiveness Analysis (2008)Funding the Unfundable (2010)Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers (2014)Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs (2017)Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements (2017)Risk, Ambiguity, and the Savage Axioms (1961)Judgment under Uncertainty: Heuristics and Biases (1975)The Framing of Decisions and the Psychology of Choice (1981)Exploration and Exploitation in Organizational Learning (1991)Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance (2007)Theory of games and economic behavior (2019)The Cochrane Library (2005)The SAGE handbook of qualitative research (2005)The Sage Handbook of Qualitative Research[1] (2006)HEALTH TECHNOLOGY REASSESSMENT: THE ART OF THE POSSIBLE (2013)A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries (2004)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report (2009)Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries (2016)Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status (2020)The economics of moral hazard: comment (1982)Methods for the Economic Evaluation of Health Care Programmes (2005)Health outcomes in economic evaluation: the QALY and utilities (2010)Linking Measured Risk Aversion to Individual Characteristics (2002)Long–Term Orientation and Intertemporal Choice in Family Firms (2011)What you Should Know about Megaprojects and Why: An Overview (2014)
this work references cited by second hop

References

  • 1988Prospect theory: An analysis of decision under risk32,475 cited
  • 2000Prospect Theory: An Analysis of Decision under Risk922 cited
  • 2002BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS216 cited
  • 2011What principles should govern the use of managed entry agreements?155 cited
  • 2009Identifying existing health care services that do not provide value for money120 cited
  • 2008Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices90 cited
  • 2010Access with Evidence Development Schemes87 cited

Cited by

  • 2016HTA Implementation Roadmap in Central and Eastern European Countries75 cited
  • 2016How OECD health systems define the range of good and services to be financed collectively24 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work